首页 › 基金 › ORBIMED ADVISORS LLC › FBRX
ORBIMED ADVISORS LLC 对 FBRX 的持仓历史
FORTE BIOSCIENCES INC
ORBIMED ADVISORS LLC 在 Q2 2026 的 13F 申报中披露持有 FBRX(FORTE BIOSCIENCES INC)1,577,705 股,市值约 US$33.5M,约占其申报组合的 0.67%,在其申报持仓中市值排名第 40 位。 ORBIMED ADVISORS LLC 最近 7 个申报季度中有 7 个季度披露了 FBRX 持仓,最早可追溯至 Q4 2024。
最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR
ORBIMED ADVISORS LLC 对 FBRX 的持仓演变
ORBIMED ADVISORS LLC 于 Q4 2024 首次披露 FBRX 持仓:600,000 股(约 US$13.6M)。 该持仓在 Q2 2026 达到峰值 1,577,705 股,市值约 US$33.5M。 在 7 次申报中,ORBIMED ADVISORS LLC 2 次增持、1 次减持、3 次保持不变。 最近一期申报(Q2 2026)显示持股 1,577,705 股、市值约 US$33.5M,环比增持 380,750 股。。 持仓曾出现大幅变动:Q2 2025 增持约 102%、Q2 2026 增持约 32%。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2024 | 600.00K | $13.63M | 新进 |
| Q1 2025 | 593.09K | $4.60M | 减持 |
| Q2 2025 | 1.20M | $15.48M | 增持 |
| Q3 2025 | 1.20M | $17.95M | 持有 |
| Q4 2025 | 1.20M | $32.64M | 持有 |
| Q1 2026 | 1.20M | $31.00M | 持有 |
| Q2 2026 | 1.58M | $33.53M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 FBRX 与 13F 数据
FBRX(FORTE BIOSCIENCES INC)的行业分类暂缺。我们追踪的基金中还有 70 只申报持有 FBRX,申报仓位最大的包括:Affinity Asset Advisors, LLC (US$24.3M), MPM BioImpact LLC (US$21.0M), TCG Crossover Management, LLC (US$19.6M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 FBRX 的基金
- Affinity Asset Advisors, LLC 1.15M 股 · $24.34M · Q2 2026
- MPM BioImpact LLC 987.45K 股 · $20.98M · Q2 2026
- TCG Crossover Management, LLC 920.00K 股 · $19.55M · Q2 2026
- Integral Health Asset Management, LLC 675.00K 股 · $14.34M · Q2 2026
- Cable Car Capital, LP 400.00K 股 · $8.50M · Q2 2026
- Boxer Capital Management, LLC 274.50K 股 · $5.83M · Q2 2026
- Trails Edge Capital Partners, LP 273.18K 股 · $5.81M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 249.69K 股 · $5.31M · Q2 2026
- Squadron Capital Management LLC 225.00K 股 · $4.78M · Q2 2026
更多关于 ORBIMED ADVISORS LLC
常见问题
How long has ORBIMED ADVISORS LLC held FBRX?
ORBIMED ADVISORS LLC has disclosed FBRX holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is ORBIMED ADVISORS LLC's current position in FBRX?
As of Q2 2026, ORBIMED ADVISORS LLC holds 1.58M shares of FBRX (FORTE BIOSCIENCES INC), valued at $33.53M, representing 0.67% of its reported portfolio and ranking #40.
Has ORBIMED ADVISORS LLC been buying or selling FBRX?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC increased its position in FBRX. The position peaked in Q2 2026 at 1.58M shares.
Which other funds hold FBRX?
Other major institutional holders of FBRX include Affinity Asset Advisors, LLC, MPM BioImpact LLC, TCG Crossover Management, LLC, among 70 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.